Oxymorphone Hydrochloride
38 NDCs across 6 manufacturers|38 Generic,0 Brand
Oxymorphone Hydrochloride is used to treat pain, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Jun 14, 2010. FDA's Orange Book lists 12 AB-rated (therapeutically equivalent) products for this ingredient.
Oxymorphone Hydrochloride is available as 38 NDCs from 6 manufacturers (38 generic, 0 brand), with NADAC prices from $0.52 to $29.51 per EA — the most expensive product costs about 57× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
38
38G / 0B
Manufacturers
6
competing in market
Price Spread
$0.52 – $29.51
per EA
7d Activity
avg +0.0% WoW · of 38 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
6 manufacturers producing OXYMORPHONE HYDROCHLORIDE
Frequently Asked Questions
What is Oxymorphone Hydrochloride used to treat?
Oxymorphone Hydrochloride is used to treat pain, per the National Library of Medicine's MED-RT classification.
When did Oxymorphone Hydrochloride become available as a generic?
FDA approved the first generic Oxymorphone Hydrochloride (ANDA) on Jun 14, 2010. The Orange Book currently lists 12 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How many Oxymorphone Hydrochloride products are on the market?
The Oxymorphone Hydrochloride drug market contains 38 NDCs from 6 manufacturers — 38 generic and 0 brand products.
What is the price range for Oxymorphone Hydrochloride?
NADAC reference prices for Oxymorphone Hydrochloride range from $0.5201 to $29.5094 per EA — the most expensive product costs about 57× the cheapest.
Which manufacturers make Oxymorphone Hydrochloride?
6 manufacturers list Oxymorphone Hydrochloride in NADAC. Ranked by number of NDCs, the largest are Amneal Pharmaceuticals LLC (14), Amneal Pharmaceuticals of New York LLC (14), KVK-Tech Inc. (4), Aurolife Pharma LLC (2), Hikma Pharmaceuticals USA Inc. (2).